Zydus Life Sciences Acquires LiqMeds Group

Published on: 

New subsidiary specializes in development of oral liquid products.

Zydus Lifesciences Limited announced that through Zydus Pharmaceuticals UK Limited, a wholly owned subsidiary, it has officially acquired LiqMeds Group, a company focused on the development, manufacturing, and supply of oral liquid products for the global market. Under terms of the acquisition, Zydus will pay an upfront amount of approximately $82.6 million with the potential for further yearly payments until 2026 depending on achievement of certain agreed milestones.


“We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities,” said Sharvil Patel, managing director, Zydus Life Sciences, in a company press release. “In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance.”

Reference: Zydus acquires UK based LiqMeds® Group. Zydus Life Sciences. October 31, 2023. Accessed October 31, 2023. https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-acquires-UK-based-LiqMeds--Group---31-10-2023.pdf